Compare Stocks: INMD, PLSE, TMDX, and AXGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$47.10 -2.5%	$45.09	$15.27 ▼ $52.91	$2.53B	1.16	1.09 million shs	951,249 shs
INMD InMode	$14.84 -0.7%	$15.06	$12.72 ▼ $16.74	$853.02M	1.86	859,774 shs	286,506 shs
PLSE Pulse Biosciences	$54.71 +3.9%	$36.93	$12.56 ▼ $55.37	$3.79B	1.63	360,514 shs	702,172 shs
TMDX TransMedics Group	$86.98 +3.2%	$79.53	$60.10 ▼ $156.00	$3.01B	1.9	1.04 million shs	574,801 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	-3.17%	-6.36%	+5.62%	+13.94%	+207.45%
INMD InMode	-0.53%	+0.13%	-2.61%	+9.77%	+3.75%
PLSE Pulse Biosciences	+1.13%	+9.52%	+39.62%	+95.55%	+248.64%
TMDX TransMedics Group	+2.49%	-8.60%	+3.36%	+18.10%	-24.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$47.10 -2.5%	$45.09	$15.27 ▼ $52.91	$2.53B	1.16	1.09 million shs	951,249 shs
INMD InMode	$14.84 -0.7%	$15.06	$12.72 ▼ $16.74	$853.02M	1.86	859,774 shs	286,506 shs
PLSE Pulse Biosciences	$54.71 +3.9%	$36.93	$12.56 ▼ $55.37	$3.79B	1.63	360,514 shs	702,172 shs
TMDX TransMedics Group	$86.98 +3.2%	$79.53	$60.10 ▼ $156.00	$3.01B	1.9	1.04 million shs	574,801 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	-3.17%	-6.36%	+5.62%	+13.94%	+207.45%
INMD InMode	-0.53%	+0.13%	-2.61%	+9.77%	+3.75%
PLSE Pulse Biosciences	+1.13%	+9.52%	+39.62%	+95.55%	+248.64%
TMDX TransMedics Group	+2.49%	-8.60%	+3.36%	+18.10%	-24.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	2.75	Moderate Buy	$51.56	9.46% Upside
INMD InMode	2.00	Hold	$16.00	7.82% Upside
PLSE Pulse Biosciences	2.60	Moderate Buy	$45.25	-17.29% Downside
TMDX TransMedics Group	2.38	Hold	$124.18	42.77% Upside

Current Analyst Ratings Breakdown

Latest INMD, PLSE, TMDX, and AXGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	TMDX TransMedics Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/26/2026	AXGN AxoGen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	AXGN AxoGen	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$60.00
8/17/2026	PLSE Pulse Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$58.00
8/10/2026	PLSE Pulse Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$45.00
8/10/2026	PLSE Pulse Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $43.00
8/6/2026	INMD InMode	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/5/2026	TMDX TransMedics Group	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$80.00 ➝ $77.00
8/5/2026	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$120.00 ➝ $100.00
8/3/2026	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$142.00 ➝ $106.00
7/30/2026	AXGN AxoGen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $53.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$225.21M	11.24	N/A	N/A	$4.77 per share	9.87
INMD InMode	$374.63M	2.28	$1.47 per share	10.07	$10.94 per share	1.36
PLSE Pulse Biosciences	$350K	10,818.51	N/A	N/A	$1.44 per share	37.99
TMDX TransMedics Group	$605.49M	4.96	$4.15 per share	20.94	$14.99 per share	5.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$15.70M	-$0.68	N/A	942.00	N/A	-13.36%	-8.90%	-6.47%	11/4/2026 (Estimated)
INMD InMode	$93.83M	$1.23	12.07	N/A	N/A	20.69%	11.99%	10.60%	10/28/2026 (Estimated)
PLSE Pulse Biosciences	-$72.78M	-$1.18	N/A	N/A	N/A	-6,755.78%	-94.42%	-79.96%	11/4/2026 (Estimated)
TMDX TransMedics Group	$190.29M	$3.89	22.36	38.15	N/A	22.69%	15.88%	5.95%	11/4/2026 (Estimated)

Latest INMD, PLSE, TMDX, and AXGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PLSE Pulse Biosciences	-$0.2933	-$0.36	-$0.0667	-$0.36	$0.53 million	$0.43 million
8/5/2026	Q2 2026	INMD InMode	$0.3460	$0.35	+$0.0040	$0.29	$94.89 million	$95.59 million
8/4/2026	Q2 2026	TMDX TransMedics Group	$0.4955	$0.44	-$0.0555	$0.41	$184.00 million	$189.95 million
7/29/2026	Q2 2026	AXGN AxoGen	$0.1214	$0.12	-$0.0014	-$0.03	$67.10 million	$69.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
INMD InMode	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.07	6.60	5.04
INMD InMode	N/A	8.18	7.28
PLSE Pulse Biosciences	N/A	9.63	9.61
TMDX TransMedics Group	1.62	6.62	6.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
INMD InMode	68.04%
PLSE Pulse Biosciences	76.95%
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.44%
INMD InMode	6.92%
PLSE Pulse Biosciences	74.00%
TMDX TransMedics Group	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	53.76 million	52.45 million	Optionable
INMD InMode	480	57.48 million	53.50 million	Optionable
PLSE Pulse Biosciences	140	69.21 million	18.00 million	Optionable
TMDX TransMedics Group	210	34.56 million	32.18 million	Optionable

INMD, PLSE, TMDX, and AXGN Headlines

Recent News About These Companies

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?

2 hours ago | zacks.com

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

4 hours ago | zacks.com

Braidwell LP Has $40.50 Million Position in TransMedics Group, Inc. $TMDX

September 3 at 4:39 AM | marketbeat.com

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

September 2 at 10:10 PM | globenewswire.com

Empowered Funds LLC Purchases New Stake in TransMedics Group, Inc. $TMDX

September 2 at 3:52 AM | marketbeat.com

193,752 Shares in TransMedics Group, Inc. $TMDX Purchased by Bank of New York Mellon Corp

September 2 at 3:14 AM | marketbeat.com

Headlands Technologies LLC Purchases Shares of 24,599 TransMedics Group, Inc. $TMDX

September 1 at 4:00 AM | marketbeat.com

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

August 31 at 10:51 PM | prnewswire.com

TransMedics to Present at Upcoming September Investor Conferences

August 31 at 4:05 PM | prnewswire.com

TransMedics Group (NASDAQ:TMDX) Trading Down 5.5% - Time to Sell?

August 31 at 12:59 PM | marketbeat.com

TransMedics Group, Inc. $TMDX Shares Sold by Beaconlight Capital LLC

August 31 at 3:28 AM | marketbeat.com

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

August 29, 2026 | globenewswire.com

Algert Global LLC Purchases 31,710 Shares of TransMedics Group, Inc. $TMDX

August 29, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and NeoGenomics (NEO)

August 26, 2026 | theglobeandmail.com

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

August 25, 2026 | prnewswire.com

EP Wealth Advisors LLC Purchases Shares of 15,401 TransMedics Group, Inc. $TMDX

August 24, 2026 | marketbeat.com

Biondo Investment Advisors LLC Purchases New Position in TransMedics Group, Inc. $TMDX

August 24, 2026 | marketbeat.com

30,456 Shares in TransMedics Group, Inc. $TMDX Acquired by Emerald Investment Advisers LLC

August 23, 2026 | marketbeat.com

Deutsche Bank AG Makes New Investment in TransMedics Group, Inc. $TMDX

August 23, 2026 | marketbeat.com

Trillium Asset Management LLC Takes $2.76 Million Position in TransMedics Group, Inc. $TMDX

August 22, 2026 | marketbeat.com

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

August 21, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMD, PLSE, TMDX, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

$47.10 -1.20 (-2.48%)

As of 04:00 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

InMode NASDAQ:INMD

$14.84 -0.11 (-0.74%)

As of 04:00 PM Eastern

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Pulse Biosciences NASDAQ:PLSE

$54.71 +2.03 (+3.85%)

As of 04:00 PM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

TransMedics Group NASDAQ:TMDX

$86.98 +2.69 (+3.19%)

As of 04:00 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMD, PLSE, TMDX, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMD, PLSE, TMDX, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMD, PLSE, TMDX, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMD, PLSE, TMDX, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

InMode NASDAQ:INMD

Pulse Biosciences NASDAQ:PLSE

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INMD, PLSE, TMDX, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INMD, PLSE, TMDX, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INMD, PLSE, TMDX, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMD, PLSE, TMDX, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

InMode NASDAQ:INMD

Pulse Biosciences NASDAQ:PLSE

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools